BioAtla IPO Presentation Deck

BioAtla - Exceptional Opportunity to Create Value Proprietary CAB Antibody Platform Advantages over traditional antibodies ■ Conditional and reversible binding enables increased antibody potency and reduced toxicity Increased drug exposure and improved pharmacokinetics Broader universe of tumor-specific antigen targets Significant Potential for Clinical Assets Two Phase 2 CAB ADCs¹ (AXL & ROR2) Phase 1 data show highly differentiated benefit/risk in patients Significant commercial potential for both assets ■ Initiated Phase 2 dosing ADC (Antibody Drug Conjugate); Immuno-oncology (1/O) Validating Global Collaboration CAB CTLA-4 BeiGene collaboration CAB CTLA-4 could be integral to future 1/0² combinations ■ $25 million in payments received from BeiGene to date; $225.5 million in potential milestones ■ Tiered royalties with highest tiers >20% bicatla Broad Development Pipeline Other differentiated CAB molecules ■ Productive platform capable of bringing forward unique CAB molecules ■ Pipeline focus on naked antibodies, bispecifics and ADCs ■Broad set of potential products

View entire presentation